Baseline Visual Acuity at Wet AMD Diagnosis Predicts Long-Term Vision Outcomes An Analysis of the IRIS Registry

Baseline Visual Acuity at Wet AMD Diagnosis Predicts Long-Term Vision Outcomes : An Analysis of the IRIS Registry

© 2020 Ho, Kleinman, Lum, et al.; licensee SLACK Incorporated.

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 51(2020), 11 vom: 01. Nov., Seite 633-639
1. Verfasser: Ho, Allen C (VerfasserIn)
Weitere Verfasser: Kleinman, David M, Lum, Flora C, Heier, Jeffrey S, Lindstrom, Richard L, Orr, Susan C, Chang, Grace C, Smith, Eleanor L, Pollack, John S
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Angiogenesis Inhibitors Vascular Endothelial Growth Factor A Ranibizumab ZL1R02VT79
Beschreibung
Zusammenfassung:© 2020 Ho, Kleinman, Lum, et al.; licensee SLACK Incorporated.
BACKGROUND AND OBJECTIVE: Clinical trials in neovascular age-related macular degeneration (nAMD) demonstrate that high visual acuity (VA) can be maintained, and low VA can be improved with anti-vascular endothelial growth factor (VEGF) treatment. Few real-world data investigating the relationship between baseline VA and long-term outcomes exist. This study compares VA at diagnosis and after treatment using data from a large patient registry
PATIENTS AND METHODS: Retrospective study of IRIS Registry patients diagnosed with nAMD in one or both eyes between January 2013 and June 2017. Patients received at least two anti-VEGF injections in the study eye(s) less than 45 days apart during the study period. Primary outcomes were the percentage of eyes with 20/40 VA or better at diagnosis and association of VA at diagnosis with longer-term visual outcomes
RESULTS: The study included 162,902 eyes. Among all included eyes, 34.3% presented with 20/40 VA or better at diagnosis. Patients with 20/40 vision or better at baseline maintained a mean VA of 20/40 or better for 2 years after treatment initiation
CONCLUSIONS: Baseline VA at nAMD diagnosis predicts long-term VA outcomes. Early diagnosis before VA is adversely affected is a key factor in preserving vision in patients with nAMD. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:633-639.]
Beschreibung:Date Completed 24.11.2021
Date Revised 31.05.2022
published: Print
Citation Status MEDLINE
ISSN:2325-8179
DOI:10.3928/23258160-20201104-05